Dysport vs Xeomin: speed, spread, formulation, and patient fit

Dysport and Xeomin are both FDA-approved botulinum toxin type A products used to treat glabellar lines (the vertical "11" lines between the brows). They share the same core mechanism — cleaving SNAP-25 at the neuromuscular junction to block acetylcholine release and temporarily relax targeted muscles. But they are not interchangeable. They differ in formulation, onset speed, diffusion pattern, unit dosing, and immunogenicity profile in ways that affect real clinical decisions.

This comparison focuses on what is actually different between them, what the label and clinical evidence say, and which patients tend to benefit from each.

What each product is

Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) was first FDA-approved in 2009 for glabellar lines. It is also approved for cervical dystonia, upper and lower limb spasticity, and pediatric lower limb spasticity. The formulation includes the 150 kDa botulinum toxin A molecule packaged with hemagglutinin and non-hemagglutinin complexing proteins, along with human serum albumin and lactose as excipients. Notably, Dysport contains cow's milk protein — patients with a known cow's milk protein allergy should not receive Dysport.

Xeomin (incobotulinumtoxinA, Merz Aesthetics) was first FDA-approved in 2010 for cervical dystonia and blepharospasm, with glabellar lines approval in 2011. In July 2024, Xeomin became the first and only US neurotoxin approved for the simultaneous treatment of upper facial lines — glabellar lines, horizontal forehead lines, and lateral canthal lines (crow's feet) — at a total dose of 64 units. The formulation is notable because it contains no complexing proteins — just the purified 150 kDa neurotoxin. This is why Xeomin is sometimes called the "naked" toxin.

Both products' labels carry the standard boxed warning about distant spread of toxin effects.

Onset: Dysport is faster

This is the most consistently reported clinical difference between the two products.

• Dysport: Onset typically 1–3 days. Some patients report visible changes within 24 hours. Full effect around 7–10 days.
• Xeomin: Onset typically 3–7 days. Full effect around 10–14 days.

The faster onset of Dysport is attributed to its broader diffusion pattern — the product spreads more widely from each injection point, reaching more neuromuscular junctions faster. For patients treating before an event, Dysport's faster timeline can be a practical advantage. For patients who want gradual, controlled changes, Xeomin's slower onset can be preferable.

Neither product's onset has been established through a head-to-head randomized trial; the comparison comes from cross-study data and extensive clinical experience.

Diffusion and spread: the most clinically relevant difference

Dysport spreads more from each injection site than Xeomin (or Botox). This has advantages and disadvantages depending on the treatment area.

Dysport's broader spread is useful for:

• Large surface areas like the forehead
• Diffuse muscle groups where wider effect is desirable
• Providers who prefer fewer injection points to cover a broader area

Dysport's broader spread is a disadvantage for:

• Precision areas where spread into adjacent muscles is unwanted (e.g., near the brow, lower forehead where brow ptosis is a risk)
• Patients with smaller treatment zones or specific anatomic concerns
• Providers who want highly localized effect

Xeomin's more contained diffusion is useful for:

• Precision areas requiring controlled placement
• Patients prone to brow ptosis or eyelid heaviness with other products
• Delicate areas where spread would be problematic

Xeomin's contained diffusion means:

• More injection points may be needed for larger areas
• Results may be more predictable in terms of exactly which muscles are affected

Unit conversion: they use completely different numbering

This is the source of significant patient confusion, and it matters.

• Dysport: The standard glabellar dose is 50 units (5 injection points, 10 units each). Dysport units are approximately 2.5–3× the numeric value of Botox/Xeomin units for equivalent clinical effect.
• Xeomin: The standard glabellar dose is 20 units (5 injection points, 4 units each). Xeomin units are approximately 1:1 with Botox units — the most straightforward conversion among all neuromodulators.

The FDA is explicit in all botulinum toxin product labels: the potency units of different botulinum toxin products are not interchangeable. A "unit" of Dysport is not the same biologic quantity as a "unit" of Xeomin. Patients switching between products should expect their provider to re-dose based on the new product's label, not simply convert their old unit count.

Per-unit pricing reflects this difference. Dysport is typically priced lower per unit ($4–$8/unit) than Xeomin ($10–$17/unit), but because Dysport requires roughly 2.5–3× more units, the total treatment cost is generally comparable. A full-face treatment with Dysport (150 units at $5/unit) costs approximately $750. A full-face treatment with Xeomin (64 units at $14/unit) costs approximately $900. Actual pricing varies significantly by geography and provider.

Duration: essentially the same

Both products last approximately 3–4 months on label for most patients. There is no consistent clinical evidence that either product meaningfully outlasts the other.

Individual duration varies more based on patient metabolism, muscle mass, dose, and injection technique than on which product is used. Some patients report 5–6 months with consistent treatment over time, but this is not a product-specific effect — it reflects the general observation that muscles "learn" to relax with repeated neuromodulator use.

The complexing protein question

Xeomin is the only FDA-approved neuromodulator that does not contain complexing proteins. Dysport, Botox, Daxxify, Jeuveau, and Letybo all include accessory proteins that surround the neurotoxin molecule.

The theoretical significance is immunogenicity. Complexing proteins are not part of the active neurotoxin — they are byproducts of the fermentation process. But they are proteins, and repeated exposure to foreign proteins can, in some patients, stimulate antibody formation. If neutralizing antibodies develop, the product stops working.

In clinical practice:

• Neutralizing antibody formation to botulinum toxin A is rare across all products (estimated at 1–5% of patients, depending on cumulative exposure)
• Xeomin's Phase III glabellar trials showed no patients developing neutralizing antibodies among 464 treated subjects in the main and open-label extension phases (per the Xeomin prescribing information)
• A head-to-head randomized trial (incobotulinumtoxinA vs. onabotulinumtoxinA, 250 subjects) demonstrated equivalence at 1 month, with 95.7% response for Xeomin and 99.2% for Botox on the Facial Wrinkle Scale, and comparable safety (Maui Derm conference summary)

The immunogenicity advantage of Xeomin is theoretical, not proven in a definitive clinical trial. But for patients who have experienced diminished response to other neuromodulators over time, switching to a protein-free formulation is a reasonable clinical strategy, supported by the theoretical rationale and the clean antibody data from Xeomin's trials.

Expanded FDA approval: Xeomin's unique advantage

In July 2024, Xeomin received FDA approval for the simultaneous treatment of all three upper facial line areas — glabellar lines, horizontal forehead lines, and lateral canthal lines — at a total labeled dose of 64 units (20 + 20 + 24). This is the only neuromodulator with this specific combined indication.

Dysport is FDA-approved for glabellar lines but the forehead and crow's feet areas are commonly treated off-label. Off-label use is routine in aesthetic medicine and not inherently problematic, but the difference in labeled indications may matter to some patients and providers.

Comparison summary

Who tends to do better with each

Dysport is often preferred for:

• Patients who want the fastest possible onset
• Treatment of broad areas (forehead, large muscle groups)
• Patients switching from Botox who want to explore a different product
• Off-label use in larger muscle areas (masseter, platysmal bands) where spread is beneficial

Xeomin is often preferred for:

• Patients who want precision placement with controlled spread
• Patients who have developed diminished response to other neuromodulators
• Long-term neuromodulator users concerned about cumulative protein exposure
• Providers who want the simplest unit conversion from Botox
• Patients who want treatment of all three upper facial areas under a single labeled indication

Neither is right for:

• Patients with known hypersensitivity to botulinum toxin products or their excipients
• Patients with active infection at injection sites
• Patients who are pregnant or breastfeeding (standard precaution for all neuromodulators)
• Patients with pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome)
• Patients taking aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission

What to ask your provider

1. Which product do you recommend for my anatomy and goals, and why? A good provider can explain their reasoning beyond brand preference.
2. How many units will I receive, and at what per-unit cost? Get a specific number. "A syringe" is not a dose.
3. How does onset and duration compare for what I want treated?
4. Have you treated patients who developed reduced response to neuromodulators over time? If you are a long-term user, ask about switching strategies.
5. What happens if I don't like the result? Neuromodulators are not reversible, but they are temporary. Ask about the plan for adjustment at follow-up.

Sources

• Dysport (abobotulinumtoxinA) Prescribing Information. accessdata.fda.gov
• Xeomin (incobotulinumtoxinA) Prescribing Information. accessdata.fda.gov
• Merz Aesthetics FDA approval of Xeomin for simultaneous upper facial lines, July 2024. firstwordpharma.com
• IncobotulinumtoxinA vs. OnabotulinumtoxinA in glabellar lines: multicenter randomized double-blinded trial. mauiderm.com
• FDA Approves IncobotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines, Pharmacy Times, 2024. pharmacytimes.com
• Xeomin FDA Approval History. drugs.com
• Dysport FDA Approval History. drugs.com
• Xeomin Patient Information Labeling. rxabbvie.com / xeominaesthetic.com